Tag Archives: ACA

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Affordable Care Act is Here to Stay

The Affordable Care Act is Here to Stay

The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future of patient access to needed medicines. In an expert panel at the 2013 BIO International Convention moderated by BioCentury’s Steve Usdin, multiple stakeholders addressed key elements of the ACA focused on both the value the ACA Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Show Me the Money: Reimbursement in an ACA World

BIO CEO 2013

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a variety of perspectives and agreed that the landscape is shifting dramatically. The reimbursement roundtable featured payors, providers, and other stakeholders discussing Affordable Care Act (ACA) implementation and the wider reimbursement landscape. With many key provisions of the ACA slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,